Mitigating Off-Label Risk, OIG Scrutiny of MSL Role
Copyright 2009 by MSL Institute, LLC. All Rights Reserved. SITEMAP
“Mitigating MSL Compliance Risk and Off-Label Prosecutions.” Reprint series from MSL Quarterly 2007 on MSL Compliance. Based on an Industry Conference Report by Tanya Douglas-Holland MD.

MITIGATING COMPLIANCE RISK AND OFF-LABEL PROMOTION PROSECUTIONS AND OIG SCRUTINY OF MEDICAL SCIENCE LIAISON ACTIVITIES 3
Introduction 3
Latest Developments in Off-Label Prosecution 3
Mitigating the Risk of Private Lawsuits for Off-Label Uses 4
Role of Office of Inspector General’s (OIG) in Monitoring Off-Label Activity and Promotion 6
Importance of Integrating Federal Trade Commission (FTC) Guidelines into a Corporate Compliance program 7
Dissemination of Off-Label Information within Frameworks of Current Case Laws, FDA Rules, and Company Policies 7
Definition of a Medical Science Liaison (MSL) Role and Evaluation of MSL Risk Tolerance Level 8
Conclusion 11
8.25×10.75″ 12 pages.
Print Magazine: Please allow 3-5 business days to ship within US (product is shipped from California). Print magazines are meant for personal use and should not be reproduced, copied, or distributed.
For internal distribution, training, or project/consulting use, please purchase PDF license.
Branded PDF (MULTI-USER): Please allow 2-24 hours for delivery, and is meant for up to 10 authorized users and will be shipped to the billing email address used in your payment. For additional users or legal use / upload within your company’s corporate intranet, please contact us at info@msliq.com or phone 1 (310) 542-5642.



